Alumis Inc. Common Stock

NASDAQ:ALMS

Biotechnology

Healthcare
$4.40 +0.91%

+$0.21 today

Market cap
$568.87M
Beta
-0.54
P/E (TTM)
-12.2
EPS (TTM)
-$1.90
52W Low $2.76High $30.60

Volume 2.01M

Average 1.31M

ALMS Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Alumis Inc. Common StockNASDAQ: ALMS

Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026

Net change in cash turns negative

Q2 FY2026 net change in cash was -$179K, compared with $23.58M a year earlier. Trailing-twelve-month net change in cash was -$88.34M. Over 3 fiscal years it compounded at +2.1% a year.

Context

  • Net change in cash amounted to 330.9% of revenue in FY2025.
  • Net change in cash increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near -$179K or moves back toward the trailing-twelve-month quarterly average of -$22.08M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$179K-99.3% QoQ
Last fiscal yearDec 2025
-$79.58M-164.4% YoY
LTMJun 2026
-$88.34M+2748.7% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.8%——
1 year-164.4%——
3-year CAGR+2.1%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(79.58M) USD
Year-over-year change
-164.4%

Net Change in Cash vs competitors

How ALMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +2748.7% is the highest of 9, against a peer median of -77.5%.
  • Net change in cash amounts to 1194.1% of revenue for ALMS, versus a peer median of 64.5%.
ALMS Competitors
Net Change in Cash for ALMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$149.83M USD+233.4%—64.5%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$100M USD-769.9%+42.0%169491.5%
ALMSAlumis Inc. Common StockLTM Jun 2026$88.34M USD+2748.7%+2.1%1194.1%
IFRXInflaRx N.V.LTM Mar 2026€22.84M EUR-203.0%-73.8%77884.9%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$21.32M USD-205.5%—7.1%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$14.65M USD+134.8%——
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$9.45M USD-46.3%-38.9%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$1.7M USD-69.1%—20.3%
TLSATiziana Life Sciences LtdFY2025$286K USD-85.9%——
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding ALMS) —-77.5%-38.9%64.5%

Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(111.93M)(154.99M)(294.23M)(243.33M)
Depreciation & Amortization250K1.28M3.15M3.5M
Deferred Income Tax000(8.56M)
Stock-Based Compensation5.96M8.63M19.46M43.52M
Change in Working Capital(1.92M)12.06M14.76M26.32M
Accounts Receivables0000
Inventory0000
Accounts Payables1.29M(642K)8.51M(6.04M)
Other Working Capital(3.21M)12.7M6.25M32.35M
Other Non-Cash Items(86K)3.05M1.79M(190.98M)
Operating Cash Flow(107.72M)(129.98M)(255.08M)(369.52M)
Capital Expenditures(2.41M)(4.5M)(1.73M)(653K)
Acquisitions (Net)0000
Purchases of Investments(209.08M)(11.28M)(240.06M)(209.17M)
Sales of Investments142.73M76.25M128M447.96M
Other Investing Activities00049.74M
Investing Cash Flow(68.75M)60.47M(113.79M)287.88M
Debt Repayment0000
Common Stock Issued00193.32M2.08M
Common Stock Repurchased000(17K)
Dividends Paid0000
Other Financing Activities1.73M(96K)40.59M0
Financing Cash Flow101.63M89.68M492.37M2.07M
Effect of Forex Changes0000
Net Change in Cash(74.85M)20.18M123.5M(79.58M)
Free Cash Flow(110.13M)(134.47M)(256.81M)(370.18M)

Alumis Inc. Common Stock

NASDAQ:ALMS

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.